Cellectis - Asset Resilience Ratio

Latest as of December 2025: 49.49%

Cellectis (ALCLS) has an Asset Resilience Ratio of 49.49% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€160.72 Million

≈ $187.90 Million USD Cash + Short-term Investments

Total Assets

€324.76 Million

≈ $379.68 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Cellectis's Asset Resilience Ratio has changed over time. Check how strategically is Cellectis's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Cellectis's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cellectis (ALCLS) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€15.62 Million	4.81%
Short-term Investments	€145.10 Million	44.68%
Total Liquid Assets	€160.72 Million	49.49%

Asset Resilience Insights

Very High Liquidity: Cellectis maintains exceptional liquid asset reserves at 49.49% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Cellectis Industry Peers by Asset Resilience Ratio

Compare Cellectis's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Cellectis (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Cellectis.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	49.49%	€160.72 Million ≈ $187.90 Million	€324.76 Million ≈ $379.68 Million	-9.80pp
2024-12-31	59.29%	€227.39 Million ≈ $265.84 Million	€383.54 Million ≈ $448.40 Million	+22.76pp
2023-12-31	36.53%	€122.11 Million ≈ $142.76 Million	€334.27 Million ≈ $390.80 Million	+29.22pp
2022-12-31	7.31%	€19.11 Million ≈ $22.34 Million	€261.22 Million ≈ $305.39 Million	-5.36pp
2021-12-31	12.67%	€48.41 Million ≈ $56.60 Million	€382.08 Million ≈ $446.69 Million	-9.41pp
2020-12-31	22.08%	€103.65 Million ≈ $121.18 Million	€469.47 Million ≈ $548.86 Million	+2.77pp
2019-12-31	19.31%	€90.28 Million ≈ $105.54 Million	€467.47 Million ≈ $546.52 Million	+8.59pp
2018-12-31	10.72%	€53.71 Million ≈ $62.79 Million	€500.84 Million ≈ $585.53 Million	-21.20pp
2016-12-31	31.93%	€105.58 Million ≈ $123.43 Million	€330.68 Million ≈ $386.60 Million	+9.94pp
2007-12-31	21.99%	€11.85 Million ≈ $13.85 Million	€53.87 Million ≈ $62.98 Million	+19.41pp
2006-12-31	2.58%	€287.00K ≈ $335.53K	€11.13 Million ≈ $13.01 Million	--

pp = percentage points

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$206.73 Million

€176.83 Million EUR

Market Cap Rank

#16416 Global

#237 in France

Share Price

€2.44

Change (1 day)

+0.41%

52-Week Range

€2.21 - €4.57

All Time High

€40.90